Dong-A ST Signed an Exclusive License Agreement with Polifarma for NESP Biosimilar DA-3880
Shots:
- Dong-A ST to receive up front and developmental/commercial milestones & be responsible to supply the finished product through STgen Bio, an affiliated Bio CDMO of Dong-A Socio Holdings. The companies collaborated for NESP biosimilar DA-3880
- Polifarma to get an exclusive license right for the development and commercialization of DA-3880 in Türkiye, Brazil, and Mexico. DA-3880 is an ARANESP/NESP biosimilar indicated for the treatment of anemic patients with chronic renal failure or those undergoing CT
- In 2014, Dong-A ST entered a license-out agreement with Sanwa Kagaku Kenkyusho for the development and commercialization of DA-3880 in Japan
Ref: Businesswire| Image: Polifarma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
